Russian National Research Medical University

Aviv Clinics and Sagol Center for Hyperbaric Medicine and Research Present Webinar on Research Findings from the First Long COVID Clinical Trial to Show Symptom Relief

Retrieved on: 
Wednesday, August 24, 2022
Forgetting, Partnership, Caregiver, Pain, New England, Brain, Shamir Medical Center, Scientific Reports, ATA, Department, Health, Hyperbaric medicine, Nebraska Department of Health & Human Services, Sagol, GLOBE, Patient, Center, The New England Journal of Medicine, Tel Aviv, HHS, Clinical trial, Oxygen, COVID, Q&A, Russian National Research Medical University, HBOT, Pharmaceutical industry, Medical imaging, Research, Tel Aviv University

ORLANDO, Fla., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Aviv Clinics and Sagol Center for Hyperbaric Medicine and Research (Sagol Center) at Shamir Medical Center announce a live webinar with Dr. Shai Efrati on Monday, August 29 at 12 p.m.

Key Points: 
  • ORLANDO, Fla., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Aviv Clinics and Sagol Center for Hyperbaric Medicine and Research (Sagol Center) at Shamir Medical Center announce a live webinar with Dr. Shai Efrati on Monday, August 29 at 12 p.m.
  • The webinar is in response to the Department of Health & Human Services (HHS) recently released National Research and Action Plan on Long COVID .
  • The clinical trial, conducted by the Sagol Center and Tel Aviv University, was first published in Scientific Reports on July 12.
  • Serving as the largest Hyperbaric center worldwide, the Sagol Center offers highly advanced, large multiplace chambers, treating more than 300 patients daily.

Pediatric Medical Centers Improve the Efficiency of Investigator-Initiated, Multi-Site, Collaborative Research with TriNetX

Retrieved on: 
Friday, July 29, 2022
RWD, Clinical, Human, Research, HIPAA, Twitter, Dean (education), Doctor of Philosophy, Health, Hospital, Children's National Hospital, National, Johns Hopkins, MMM, United Nations Research Institute for Social Development, Parent, Johns Hopkins All Children's Hospital, FASA, Nursing, Recruitment, News, Rodale, Inc., U.S. News & World Report, Harwell Science and Innovation Campus, GDPR, EHR, Patient, PCN, No, Russian National Research Medical University, Engagement, Pharmaceutical industry, Medicine, D.C, Child, MD

Representatives from the participating pediatric medical centers meet monthly to propose and evaluate new collaborative research opportunities, introduce potential co-investigators, and pursue peer-reviewed publications.

Key Points: 
  • Representatives from the participating pediatric medical centers meet monthly to propose and evaluate new collaborative research opportunities, introduce potential co-investigators, and pursue peer-reviewed publications.
  • Additional pediatric medical centers are welcome to join the collaborative and are encouraged to contact TriNetX.
  • "Together, through the Pediatric Collaboratory Network, we hope to catalyze innovative clinical trials and lower the barriers to multi-site, investigator-initiated research."
  • "Participation in the Pediatric Collaboratory Network is open and encouraged for all researchers interested in pediatric research that join the TriNetX global health research network."

RSNA R&E Foundation Approves Over $4 Million in Grant Funding

Retrieved on: 
Tuesday, July 19, 2022
Linda, Research, Radiological Society of North America, Patient, Radiology, OAK, Foundation, Director, Russian National Research Medical University, Society, Board, Medicine, Health, Trustee, Association, Board of directors, Radiation, RSNA, R, Pharmaceutical industry, Education

Since the R&E Foundation's inception in 1984, it has awarded over $70 million in grant funding.

Key Points: 
  • Since the R&E Foundation's inception in 1984, it has awarded over $70 million in grant funding.
  • Since the R&E Foundation's inception in 1984, it has awarded over $70 million in grant funding.
  • "Through the generosity of our donors, the RSNA R&E Foundation is able to seed the future of radiology," said Vijay M. Rao, M.D., chair of the R&E Foundation Board of Trustees.
  • Grant recipients have received 50 additional dollars in subsequent funding from other sources for every dollar funded by the Foundation, making the impact of that funding even greater.

Asensus Surgical Announces Purchase of Senhance Robotic System by Loginov Moscow Clinical Scientific Center

Retrieved on: 
Monday, September 27, 2021
Technology, Surgery, Medical Devices, FDA, Other Technology, Software, Health, Pharmaceutical, Data Management, Goal, Robot-assisted surgery, ISU, Securities Act of 1933, Hope, Deep learning, Health, Digital, Annual report, Security (finance), Sale, Private Securities Litigation Reform Act, Image, U.S. Securities and Exchange Commission, Surgeon, Patient, Surgery, MCSC, Russian National Research Medical University, CEO, Program, 3D, Intelligence, Securities Exchange Act of 1934, Research, Machine learning, Movement, NYSE, Loginov, SEC, Department, Dentistry, Loginov Moscow Clinical Scientific Center, Asensus Surgical, Inc., LOGINOV MOSCOW CLINICAL SCIENTIFIC CENTER, ASENSUS SURGICAL, INC.

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery, today announced that Loginov Moscow Clinical Scientific Center, located in Moscow, Russia, has initiated its Senhance Robotic Surgery program following the purchase of a Senhance Surgical System.

Key Points: 
  • Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery, today announced that Loginov Moscow Clinical Scientific Center, located in Moscow, Russia, has initiated its Senhance Robotic Surgery program following the purchase of a Senhance Surgical System.
  • The Senhance Surgical System is powered by the Intelligent Surgical Unit (ISU).
  • The Loginov Moscow Clinical Scientific Center (The Loginov MCSC) is one of the largest and most innovative institutions funded by the Moscow Health Department.
  • This press release includes statements relating to the Senhance Surgical System and The Loginov Moscow Clinical Scientific Center hospital initiating a program with the Senhance System.

Scientists Improve Contrast In Noninvasive Imaging of Cancer Cells, NUST MISIS reports

Retrieved on: 
Monday, May 17, 2021
Articles, Physical sciences, National University of Sciences & Technology, Nanobiotechnology, Natural sciences, Nanoshell, Nanomaterials, Russian National Research Medical University, Ferroxidase, Fluorescence

However, any synthetic contrast agent for cell labeling has acritical drawback it dilutes asthe cells divide, which leads toloss ofthe signal after several cycles ofdivisions.

Key Points: 
  • However, any synthetic contrast agent for cell labeling has acritical drawback it dilutes asthe cells divide, which leads toloss ofthe signal after several cycles ofdivisions.
  • These include, for example, fluorescent proteins orenzymes with ferroxidase activity," saysMaxim Abakumov, head ofthe NUST MISIS Biomedical Nanomaterials Laboratory, senior researcher atthe Medicinal Nanobiotechnology Department, N.I.
  • Pirogov Russian National Research Medical University.\nAteam ofscientists from NUST MISIS, V. Serbsky National Medical, N.I.
  • Also, coexpression ofencapsulin nanoshells, ferroxidase cargo, and iron transporter led toanincrease incontrast inmagnetic resonance imaging ofcancer cells.\n'

Scientists Improve Contrast In Noninvasive Imaging of Cancer Cells, NUST MISIS reports

Retrieved on: 
Monday, May 17, 2021
Articles, Physical sciences, National University of Sciences & Technology, Nanobiotechnology, Natural sciences, Nanoshell, Nanomaterials, Russian National Research Medical University, Ferroxidase, Fluorescence

However, any synthetic contrast agent for cell labeling has acritical drawback it dilutes asthe cells divide, which leads toloss ofthe signal after several cycles ofdivisions.

Key Points: 
  • However, any synthetic contrast agent for cell labeling has acritical drawback it dilutes asthe cells divide, which leads toloss ofthe signal after several cycles ofdivisions.
  • These include, for example, fluorescent proteins orenzymes with ferroxidase activity," saysMaxim Abakumov, head ofthe NUST MISIS Biomedical Nanomaterials Laboratory, senior researcher atthe Medicinal Nanobiotechnology Department, N.I.
  • Pirogov Russian National Research Medical University.\nAteam ofscientists from NUST MISIS, V. Serbsky National Medical, N.I.
  • Also, coexpression ofencapsulin nanoshells, ferroxidase cargo, and iron transporter led toanincrease incontrast inmagnetic resonance imaging ofcancer cells.\n'